VX 15

Drug Profile

VX 15

Alternative Names: Anti-SEMA4D antibody - Vaccinex; VX15; VX15/2503; VX15/anti-SEMA4D antibody

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Vaccinex
  • Developer Teva Pharmaceutical Industries; Vaccinex
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD100 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Huntington's disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Huntington's disease
  • Phase I Multiple sclerosis; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 23 Jan 2017 Phase-I clinical trials in Non-small cell lung cancer in USA (IV) before January 2017 (Vaccinex pipeline, January 2017)
  • 06 Oct 2016 Vaccinex enters into a collaborative agreement with Merck KGaA for a phase Ib/II trial of VX 15 in non-small cell lung cancer (Late-stage disease, Combination therapy)
  • 20 Sep 2016 Anti-semaphorin 4D antibody technology licensed to Vaccinex for the treatment of Huntington's disease and Multiple sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top